Cart
sales@molnova.com
Plonmarlimab
CAS No. 2377482-36-3
Plonmarlimab( —— )
Catalog No. M36822 CAS No. 2377482-36-3
Plonmarlimab (TJ003234) is an anti-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody with potential antiviral activity for the study of immune diseases and novel coronavirus infections.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 687 | In Stock |
|
| 10MG | 937 | In Stock |
|
| 25MG | 1416 | In Stock |
|
| 50MG | 1832 | In Stock |
|
| 100MG | 2502 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePlonmarlimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPlonmarlimab (TJ003234) is an anti-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody with potential antiviral activity for the study of immune diseases and novel coronavirus infections.
-
DescriptionPlonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
Recptorc-Fms | SARS-CoV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2377482-36-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bonaventura A, et al. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front Immunol. 2020 Jul 3;11:1625. ?
molnova catalog
related products
-
AZD7507
AZD7507 (AZD-7507) is a potent, selective, orally available CSF-1R (c-FMS) with IC50 of 32 nM.
-
JNJ-6204
JNJ-6204 is a dual inhibitor of CSNK1D (IC50 = 2.3 nM) and CSNK1E (IC50 = 137 nM).
-
Emactuzumab
Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM.
